CNMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CNMD is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has some fundamental improvement in Q1 and better full-year guidance, but the current price trend is still weak, analyst sentiment is cautious, and there is no strong proprietary buy signal. I would not buy it today; the better call is to wait.
Technically, CNMD looks weak. The stock closed at 35.56, below the pivot at 37.922 and near support at 35.865, with the next support at 34.594. MACD histogram is negative and expanding, which confirms downside momentum. RSI_6 at 41.15 is neutral but not oversold enough to signal a strong entry. The moving averages are bearish, with SMA_200 > SMA_20 > SMA_5, showing the broader trend is still down. The short-term pattern data suggests only modest near-term upside and weak one-month performance.
Q1 results showed improving profitability, with net income more than doubling and EPS rising sharply year over year. Gross margin also improved materially. The company completed the divestiture of certain GI products, which supports a cleaner focus on higher-growth offerings. Management also raised its 2026 organic revenue growth forecast to 5.0% to 6.5%, which is a constructive catalyst.
Revenue still declined 1.3% year over year in Q1, so top-line growth remains soft. Analysts have turned more cautious, including a downgrade from Piper Sandler and lower price targets from JPMorgan. The company is still dealing with execution concerns and a lack of clear catalysts. Trading trends from hedge funds and insiders are neutral, and there is no recent congress trading activity to support a bullish case.
In Q1 2026, CONMED showed mixed but improving fundamentals. Revenue was $317.0 million, down 1.31% year over year, but profitability improved sharply: net income rose 129.09% to $13.8 million, EPS increased 136.84%, and gross margin expanded to 57.86%. This is a solid earnings-quality improvement quarter, especially given the stronger guidance, but it is not yet showing strong revenue acceleration.
Analyst sentiment has softened recently. On 2026-04-30, JPMorgan lowered its target to $40 from $43 and kept Neutral. On 2026-03-18, Wells Fargo initiated at Equal Weight with a $42 target. On 2026-03-17, Piper Sandler downgraded CNMD to Neutral from Overweight and cut its target to $39 from $55, citing execution issues and limited catalysts. Overall Wall Street is neutral-to-cautious rather than bullish.
